All In Biotech

Drug Trial Radar · NCT04717414

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

313

Actual

Start

Feb 25, 2021

Primary completion

May 26, 2025

Study completion Aug 18, 2032

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus kinase 2 (JAK2) inhibitor therapy and who require red blood cell count (RBC) transfusions. The study is divided into Screening Period, a Treatment Phase (consisting of a Blinded Core Treatment Period, a Day 169 Response Assessment, a Blinded Extension Treatment Period, and an Open-label Extension Treatment Period), and a Posttreatment Follow-up Period. Following the Day 169 Response Assessment, subjects who did not show clinical benefit will have the option to unblind. Subjects who were on placebo during the Blinded Core Treatment Period will have the opportunity to crossover into the Open-Label Extension Treatment Period and receive Luspatercept.

Conditions

  • Myeloproliferative Disorders
  • Myelofibrosis
  • Primary Myelofibrosis
  • Post-Polycythemia Vera Myelofibrosis
  • Anemia

Interventions

  • ACE-536Drug

    Subcutaneous Injection

  • PlaceboOther

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12)Time frame: From randomization to week 36 (Approximately 36 Weeks)

Locations

185 sites in 26 countries. Site status is shown where the registry gives one.

  • Local Institution - 110

    Los Angeles, California

  • Local Institution - 135

    Orlando, Florida

  • Local Institution - 133

    Plantation, Florida

  • Local Institution - 112

    Chicago, Illinois

  • Local Institution - 124

    Lexington, Kentucky

  • Local Institution - 114

    Ann Arbor, Michigan

  • Local Institution - 108

    St Louis, Missouri

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Mount Sinai Medical Center

    New York, New York

  • University of Pittsburg Medical Center

    Pittsburgh, Pennsylvania

  • Allegheny Health Network

    Pittsburgh, Pennsylvania

  • Local Institution - 130

    Knoxville, Tennessee

  • The University of Texas - MD Anderson Cancer Center

    Houston, Texas

  • Local Institution - 119

    Salt Lake City, Utah

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Local Institution - 172

    Ciudad Autónoma de BuenosAires, Buenos Aires, Argentina

  • Hospital Italiano de La Plata

    La Plata, Buenos Aires, Argentina

  • Gosford Hospital

    Gosford, Australia

  • Royal Hobart Hospital

    Hobart, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • The Alfred Hospital

    Melbourne, Victoria, Australia

  • Sir Charles Gairdner Hospital

    Nedlands, Western Australia, Australia

  • Local Institution - 272

    Graz, Austria

  • Krankenhaus der Elisabethinen Linz, I Interne Abteilung

    Linz, Austria

  • Local Institution - 271

    Vienna, Austria

  • Local Institution - 274

    Vienna, Austria

  • Local Institution - 318

    Bruges, Belgium

  • Local Institution - 312

    Brussels, Belgium

  • Local Institution - 313

    Hasselt, Belgium

  • Uz Leuven

    Leuven, Belgium

  • Local Institution - 319

    Liège, Belgium

  • Local Institution - 316

    Roeselare, Belgium

  • Local Institution - 315

    Verviers, Belgium

  • Cliniques Universitaires UCL de Mont-Godine

    Yvoir, Belgium

  • Local Institution - 181

    Calgary, Alberta, Canada

  • Local Institution - 179

    Edmonton, Alberta, Canada

  • Local Institution - 183

    Vancouver, British Columbia, Canada

  • University Hospital - London Health Sciences Centre

    London, Ontario, Canada

  • Local Institution - 180

    Toronto, Ontario, Canada

  • Local Institution - 177

    Montreal, Quebec, Canada

Showing 40 of 185 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.